Neuropathy After Breast Cancer Chemo Can Last for Years
Early-stage breast cancer (ESBC) patients who receive adjuvant chemotherapy can experience symptoms of peripheral neuropathy even years after completing therapy, resulting in reduced quality of life, say US researchers, who call for clinicians to consider the long-term impact of their therapeutic choices.
After a systematic review of current evidence on peripheral neuropathy in ESBC turned up precious little information, the team studied data on more than 1500 women who had received various combinations of adjuvant chemotherapy as part of a randomized clinical trial.
They found that women given either adjuvant doxorubicin and docetaxel or concurrent doxorubicin, cyclophosphamide, and docetaxel, rather than a regimen with higher cumulative doses of docetaxel, were approximately half as likely to develop severe, long-term peripheral neuropathy, an outcome that was associated with significant reductions in quality-of-life scores.
Pages: 1 2 3 4 5 6 7 8 9 10